WO2004089313A3 - Nouvelles formes de l'olanzapine et methodes de traitement associees - Google Patents

Nouvelles formes de l'olanzapine et methodes de traitement associees Download PDF

Info

Publication number
WO2004089313A3
WO2004089313A3 PCT/US2004/009947 US2004009947W WO2004089313A3 WO 2004089313 A3 WO2004089313 A3 WO 2004089313A3 US 2004009947 W US2004009947 W US 2004009947W WO 2004089313 A3 WO2004089313 A3 WO 2004089313A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
forms
related methods
novel
olanzapine
Prior art date
Application number
PCT/US2004/009947
Other languages
English (en)
Other versions
WO2004089313A2 (fr
Inventor
Magali Bourghol Hickey
Julius Remenar
Original Assignee
Transform Pharmaceuticals Inc
Magali Bourghol Hickey
Julius Remenar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2003/027772 external-priority patent/WO2004078161A1/fr
Priority claimed from US10/660,202 external-priority patent/US7927613B2/en
Priority claimed from PCT/US2003/041642 external-priority patent/WO2004060347A2/fr
Priority claimed from US10/747,742 external-priority patent/US7790905B2/en
Priority claimed from PCT/US2004/006288 external-priority patent/WO2004078163A2/fr
Application filed by Transform Pharmaceuticals Inc, Magali Bourghol Hickey, Julius Remenar filed Critical Transform Pharmaceuticals Inc
Priority to US10/551,014 priority Critical patent/US20060223794A1/en
Publication of WO2004089313A2 publication Critical patent/WO2004089313A2/fr
Publication of WO2004089313A3 publication Critical patent/WO2004089313A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouvelles formes solubles de l'olanzapine. Parmi ces formes figurent des sels, des co-cristaux et des solvates de l'olanzapine. Cette invention concerne également de nouvelles compositions pharmaceutiques contenant lesdites nouvelles formes solubles ainsi que des méthodes de traitement associées. Les compositions et méthodes de la présente invention sont utiles dans le traitement de la psychose et de troubles fonctionnels intestinaux.
PCT/US2004/009947 2002-02-15 2004-03-31 Nouvelles formes de l'olanzapine et methodes de traitement associees WO2004089313A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/551,014 US20060223794A1 (en) 2002-02-15 2004-03-31 Novel olanzapine forms and related methods of treatment

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US45950103P 2003-04-01 2003-04-01
US60/459,501 2003-04-01
US48706403P 2003-07-11 2003-07-11
US48671303P 2003-07-11 2003-07-11
US60/487,064 2003-07-11
US60/486,713 2003-07-11
USPCT/US03/27772 2003-09-04
PCT/US2003/027772 WO2004078161A1 (fr) 2003-02-28 2003-09-04 Compositions co-cristallines pharmaceutiques de medicaments, notamment de carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophene, aspirine, flurbiprofene, phenytoine et ibuprofene
US10/660,202 2003-09-11
US10/660,202 US7927613B2 (en) 2002-02-15 2003-09-11 Pharmaceutical co-crystal compositions
USPCT/US03/41642 2003-12-29
PCT/US2003/041642 WO2004060347A2 (fr) 2002-09-03 2003-12-29 Compositions pharmaceutiques de solvates de propylene glycol
US10/747,742 US7790905B2 (en) 2002-02-15 2003-12-29 Pharmaceutical propylene glycol solvate compositions
US10/747,742 2003-12-29
USPCT/US04/06288 2004-02-26
PCT/US2004/006288 WO2004078163A2 (fr) 2003-02-28 2004-02-26 Compositions pharmaceutiques a base d'un co-cristal
US54834304P 2004-02-27 2004-02-27
US60/548,343 2004-02-27

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2003/019574 Continuation-In-Part WO2004000284A1 (fr) 2002-02-15 2003-06-20 Compositions pharmaceutiques a dissolution amelioree
US10/601,092 Continuation-In-Part US20050025791A1 (en) 2002-02-15 2003-06-20 Pharmaceutical compositions with improved dissolution
US10/747,742 Continuation US7790905B2 (en) 2002-02-15 2003-12-29 Pharmaceutical propylene glycol solvate compositions

Publications (2)

Publication Number Publication Date
WO2004089313A2 WO2004089313A2 (fr) 2004-10-21
WO2004089313A3 true WO2004089313A3 (fr) 2005-11-24

Family

ID=33163281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/009947 WO2004089313A2 (fr) 2002-02-15 2004-03-31 Nouvelles formes de l'olanzapine et methodes de traitement associees

Country Status (1)

Country Link
WO (1) WO2004089313A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
JP2006500377A (ja) 2002-06-21 2006-01-05 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 改善された溶解性を有する医薬組成物
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
PL377084A1 (pl) * 2005-09-15 2007-03-19 Koźluk Tomasz Nobilus Ent Nowe związki olanzapiny i sposób ich wytwarzania
ATE465720T1 (de) * 2006-07-05 2010-05-15 Bilim Ilac Sanayii Ve Ticaret Stabile olanzapin-formulierung mit antioxidantien
DE102006032426A1 (de) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung
DE102006032427A1 (de) * 2006-07-13 2008-01-17 Neuraxpharm Arzneimittel Gmbh U. Co. Kg Verwendung von Zusammensetzungen von Clozapin, Quetiapin, schwer oder sehr schwer löslichen Säureadditionssalzen von Quetiapin und/oder Olanzapin zur Herstellung von Lösungen zur oralen Verabreichung
NZ589742A (en) 2008-05-27 2012-06-29 Univ Melbourne Methods of treating mammals with eustachian tube dysfunctions with betahistine
EP2292624A1 (fr) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Processus de purification d'olanzapine
US8513236B2 (en) 2010-02-03 2013-08-20 Laurus Labs Private Limited Pterostilbene cocrystals
AU2012221704B2 (en) 2011-02-23 2013-12-05 Coeruleus Ltd. Flumazenil complexes, compositions comprising same and uses thereof
CN113200949B (zh) * 2021-04-16 2022-11-29 天津大学 一种二甲胺含笑内酯-水杨酸盐及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703232A (en) * 1995-03-24 1997-12-30 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
US5736541A (en) * 1995-03-24 1998-04-07 Eli Lilly And Company Olanzapine polymorph crystal form
US6348458B1 (en) * 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703232A (en) * 1995-03-24 1997-12-30 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
US5736541A (en) * 1995-03-24 1998-04-07 Eli Lilly And Company Olanzapine polymorph crystal form
US6348458B1 (en) * 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine

Also Published As

Publication number Publication date
WO2004089313A2 (fr) 2004-10-21

Similar Documents

Publication Publication Date Title
IL171170A (en) History of itensinoids and their pharmaceutical preparations, methods of preparation and use thereof
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2005046603A3 (fr) Composes pyridiniques
WO2004110357A3 (fr) Composes heterocycliques et leurs utilisations
WO2004006858A3 (fr) Composes, compositions et methodes d'utilisation de ces derniers
WO2006058236A3 (fr) Composition et methode pour traiter des affections neurologiques
EP1622589A4 (fr) Compositions, cibles, methodes et dispositifs pour le traitement de troubles oculaires et peri-oculaires
WO2004078116A3 (fr) Inhibiteurs de la p 38 et leurs procedes d'utilisation
WO2007044026A3 (fr) Compositions comportant du collagène modifié et leurs utilisations
EP2213684A3 (fr) Anticorps nogo-a pour le traitement de la maladie d'Alzheimer
WO2004089313A3 (fr) Nouvelles formes de l'olanzapine et methodes de traitement associees
GB0312832D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
WO2004009062A3 (fr) Antagonistes du recepteur nmda et leur utilisation pour inhiber l'hyperphosphorylation de la proteine associee aux microtubules tau
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
WO2005030144A3 (fr) Composes de pyrrolopyridazine, et procedes pour les utiliser pour traiter des troubles de proliferation
WO2005105753A8 (fr) Derives naphthalimides, procedes de fabrication et compositions pharmaceutiques les renfermant
WO2005099702A3 (fr) Derives de r(?)-11-hydroxyaporphines et utilisations de ces derives
WO2005016883A3 (fr) Derives d'acrylamide servant d'antagonistes de l'integrine vla-1, et leurs utilisations
IL171384A (en) Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders
WO2006135694A3 (fr) Composes modulateurs d'uii et utilisation
WO2004105773A3 (fr) Utilisation de s1p
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
WO2004026253A3 (fr) Nouveaux composes de lapacho et procedes d'utilisation associes
WO2006024958A3 (fr) Compositions cannabinoides et procedes d'utilisation correspondants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006223794

Country of ref document: US

Ref document number: 10551014

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 10551014

Country of ref document: US